Kumar, S K
Ma, E
Engebretson, A E
Buadi, F K
Lacy, M Q
Dispenzieri, A
Duh, M S
Lafeuille, M-H
Lefebvre, P
Cheng, W Y
Dea, K
Rembert, D
Patt, D
Niculescu, L
Quick, M
Rajkumar, S V
Article History
First Online: 14 August 2015
Competing interests
: Dr Kumar has acted as a consultant for Merck, Celgene, Millennium Pharmaceuticals, Inc and Onyx; and has received research funding from Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Celgene, Novartis, Genzyme, Onyx and Cephalon. Ms Ma, Dr Niculescu and Dr Quick are employees of Millennium Pharmaceuticals, Inc. Dr Lacy has received research funding from Celgene Corporation. Dr Dispenzieri has received research funding from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Pfizer, Celgene Corporation and Janssen. Dr Duh, Ms Lafeuille, Mr Lefebvre, Ms Cheng and Ms Dea have received research funding from Millennium Pharmaceuticals, Inc, via engagement with employer Analysis Group Inc. Dr Rembert and Dr Patt are employees of McKesson Specialty Health Ms Engebretson, Dr Buadi and Dr Rajkumar declare no conflict of interest.